Loading…
Currax Pharmaceuticals LLC, a pharmaceutical drug manufacturer, received an FDA Warning Letter on September 22, 2020. Based on the limited metadata available, the specific nature of the violations cannot be determined as no subject line was provided. This warning was issued by the FDA's drug regulatory division and indicates that the agency identified significant compliance concerns requiring immediate corrective action from the company.